New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
06:34 EDTJAZZJazz Pharmaceuticals trades at attractive risk/reward, says Piper Jaffray
Piper Jaffray believes Jazz Pharmaceuticals' acquisition of the U.S. rights to Defitelio makes the company's long-term growth story even more attractive. Piper says Jazz shares trade at an attractive risk/reward and it reiterates an Overweight rating on the name with a $200 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
06:17 EDTJAZZJazz Pharmaceuticals assumed with a Buy at Citigroup
Price target lowered to $195 from $202.
March 26, 2015
07:30 EDTJAZZDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 18, 2015
13:05 EDTJAZZJazz Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use